ASHP: ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm. 2006, 63: 1172-1193.
Castiglia L, Miraglia N, Pieri M, Simonelli A, Basilicata P, Genovese G, Guadagni R, Acampora A, Sannolo N, Scafarto MV: Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department. J Occup Health 2008, 50: 48-56. 10.1539/joh.50.48
Connor TH, Anderson RW, Sessink PJM, Spivey SM: Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm 2002, 59: 68-72.
Connor TH, Sessink PJM, Harrison BR, Pretty JR, Peters BG, Alfaro RM, Bilos A, Beckmann G, Bing MR, Anderson LM, DeChristoforo R: Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies. Am J Health-Syst Pharm 2005, 62: 475-484.
Ensslin AS, Huber R, Pethran A, Römmelt H, Schierl R, Kulka U, Fruhmann G: Biological monitoring of hospital pharmacy personnel occupatonally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997, 70: 205-208. 10.1007/s004200050208
Ensslin AS, Stoll Y, Pethran A, Pfaller A, Rommelt H, Fruhmann G: Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994, 51: 229-233. 10.1136/oem.51.4.229
Fujita H: Alkylating agents (section 2), pharmacokinetics of antineoplastic drugs. Medical Review, Japan; 1986.
Harrison B, Peters BG, Bing MR: Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer deviceversus standard preparation techniques. Am J Health-Syst Pharm 2006, 63: 1736-1744. 10.2146/ajhp050258
Hedmer M, Georgiadi A, Bremberg ER, Jonsson BAG, Eksborg S: Surface contamination of Cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann occupHyg 2005, 49: 629-637.
Hedmer M, Tinnerberg H, Axmon A, Jonsson BAG: Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2008, 81: 899-911. 10.1007/s00420-007-0284-y
International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice: Safe handling of cytotoxics. J Oncol PharmPract 2007, 13: 1-81.
Kitada M, Katou H, Nakayama S, Hama T, Sugiura S: The revised version of guideline of handling antineoplastic drugs in medical center–Manual of handling antineoplastic drugs. YakujiNippo Co, Tokyo, Japan; 2009.
McDevitt JJ, Lees PS, McDiarmad MA: Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 1993, 35: 57-60.
McDiarmid MA, Oliver MS, Roth TS, Rogers B, Escalante C: Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. JOEM 2010, 52: 1028-1034.
Mochizuki C, Fijikawa I, Tei G, Yoshida J: A comparison of cleaning solutions in the biological safety cabinet for preparation of anti-cancer agents. J. Jpn. Soc. Hosp. Pharm 2008, 44: 601-604.
Nabeshima T, Sugiura S, Nakanishi H, Tanimura M, Hashida T, Syoji T, Nakao M: Guideline for aseptic handling of injection and antineoplastic drugs. YakujiNippo Co., Tokyo, Japan; 2008.
National Institute for Occupational Safety and Health (NIOSH) Department of Health and Human Service (DHHS). NIOSH ALERT (2004) preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings 2004. http://www.cdc.gov/niosh/docs/2004-165/pdfs/
Nyman HA, Jorgenson JA, Slawson MH: Workplace contamination with antineoplastic agents in a NEW cancer hospital using a closed-system drug transfer device. Hospital Pharmacy 2007, 42: 219-225. 10.1310/hpj4203-219
Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D: Uptake of antineoplastic agents in pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health; 2003, 76: 5-10.
Sasaki M, Dakeishi M, Hoshi S, Ishii N, Murata K: Assessment of DNA damage in Japanese nurses handling antineoplastic drugs by the comet assay. J Occup Health 2008, 50: 7-12. 10.1539/joh.50.7
Schreiber C, Radon K, Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D: Uptake of antineoplastic agents in pharmacy personnel. Part II: study of work-related risk factofs. Int Arch Occup Environ Health 2003, 76: 11-16.
Selevan SG, Lindbohm M-L, Hornung RW, Hemminki K: A study of occupational exposure to antineoplastic drugs and fetal lossin nurses. N Engl J Med 1985, 313: 1173-1178. 10.1056/NEJM198511073131901
Sessink PJM, Anzion RB, Van Den Broek PHH, Bos RP: Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Week Sci 1992, 14: 16-22. 10.1007/BF01989220
Sessink PJM, Boer KA: Scheefhals APH. Anzion RBM, Bos RP (1992) Occupational exposure to antineoplastic agents at several departments in a hospital. Int Arch Occup Environ Health 1992, 64: 105-112. 10.1007/BF00381477
Sessink PJM, Connor TH, Jorgenson JA, Tyler TG: Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Practice 2011, 17: 39-48. 10.1177/1078155210361431
Sessink PJM, Kroese ED, Kranen HJ, Bos RP: Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. In Arch Occup Environ Health 1995, 67: 317-323. 10.1007/BF00385647
Sessink PJM, Van De Kerkhof MCA, Anzion RBM, Noordhoek J, Bos RP: Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environ Health 1994, 49: 165-169. 10.1080/00039896.1994.9940377
Sessink PJM, Wittenhorst BCJ, Anzion RBM, Bos RP: Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health 1997, 52: 240-244. 10.1080/00039899709602893
Sugiura S, Nakanishi H, Asano M, Hashida T, Tanimura M, Hama T, Nabeshima T: Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan. J Oncol Pharm Practice 2011, 17: 20-28. 10.1177/1078155210369851
Tanimura M, Yamada K, Sugiura S, Mori K, Nagata H, Tadokoro K, Miyake T, Hamaguchi Y, Sessink PJM, Nabeshima T: An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a Japanese community hospital designated for the treatment of cancer. J Health Sci 2009, 55: 750-756. 10.1248/jhs.55.750
The Japanese society of hospital pharmacists: J Jpn. Soc. Hosp.. 2012, 48: 501-556.
Valanis B, Vollmer W, Labuhn K, Glass A: Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med 1997, 39: 574-580. 10.1097/00043764-199706000-00013
Valanis B, Vollmer WM, Steele P: Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 1999, 41: 632-638. 10.1097/00043764-199908000-00004
Vandenbroucke J, Robays H: How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice 2001, 6: 146-152. 10.1177/107815520100600403
Wick C, Slawson MH, Jorgenson JA, Tyler LS: Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm 2003, 60: 2314-2320.
Yoshida J, Koda S, Nishida S, Yoshida T, Miyajima K, Shinji K: Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in japan. J Oncol Pharm Practice 2011, 17: 29-38. 10.1177/1078155210380485
Yoshida J, Kosaka H, Tomioka K, Kumagai S: Genotoxic risk to nurses from contamination of the work environment with antineoplastic drugs in japan. J Occup Health 2006, 48: 517-522. 10.1539/joh.48.517
Yoshida J, Tei G, Mochizuki C, Masu Y, Koda S, Kumagai S: Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann OccupHyg 2009, 53: 153-160.